azapropazone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
anti-inflammatory analgesics, phenylbutazone derivatives 266 13539-59-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • AHR-3018
  • apazone dihydrate
  • azapropazone
  • azapropazone dihydrate
  • apazone
  • cinnamin
  • cinnopropazone
  • prolixan
An anti-inflammatory agent used in the treatment of rheumatoid arthritis. It also has uricosuric properties and has been used to treat gout.
  • Molecular weight: 300.36
  • Formula: C16H20N4O2
  • CLOGP: 1.78
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 0
  • TPSA: 56.22
  • ALOGS: -2.66
  • ROTB: 2

Drug dosage:

DoseUnitRoute
0.75 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.06 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 60 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 89.18 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.12 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.14 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.00 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 17 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1972 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC M01AX04 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Other antiinflammatory and antirheumatic agents, non-steroids
MeSH PA D000700 Analgesics
MeSH PA D018712 Analgesics, Non-Narcotic
CHEBI has role CHEBI:35841 uricosuric drug
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory drug
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D018501 Antirheumatic Agents
MeSH PA D006074 Gout Suppressants
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
MeSH PA D014528 Uricosuric Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Ankylosing spondylitis indication 9631008 DOID:7147
Rheumatoid arthritis indication 69896004 DOID:7148
Gout indication 90560007 DOID:13189
Osteoarthritis indication 396275006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.24 acidic
pKa2 0.41 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Xanthine dehydrogenase/oxidase Enzyme WOMBAT-PK
Prostaglandin G/H synthase 1 Enzyme WOMBAT-PK

External reference:

IDSource
D001032 MESH_DESCRIPTOR_UI
N0000167162 NUI
C0003524 UMLSCUI
D02966 KEGG_DRUG
329543000 SNOMEDCT_US
391798003 SNOMEDCT_US
1029 RXNORM
003712 NDDF
BF18764H96 UNII
22304-30-9 SECONDARY_CAS_RN
CHEBI:38010 CHEBI
2276 INN_ID
AZQ PDB_CHEM_ID
DB07402 DRUGBANK_ID
26098 PUBCHEM_CID
CHEMBL1565476 ChEMBL_ID

Pharmaceutical products:

None